CD-59 is involved in ___________.

Correct Answer: C. Paroxysmal nocturnal hemoglobinuria

CD59 is a complement regulatory protein (membrane inhibitor of reactive lysis, MIRL) that protects cells from complement-mediated destruction by inhibiting the formation of the membrane attack complex (MAC, C5b-9). In paroxysmal nocturnal hemoglobinuria (PNH), mutations in the PIGA gene (X-linked) prevent the synthesis of glycosylphosphatidylinositol (GPI) anchors, which normally tether CD59 (and CD55) to the cell membrane. Without these anchors, CD59 and other complement regulators are absent from the surface of hematopoietic cells—particularly red blood cells, platelets, and white blood cells. This leaves these cells defenseless against complement-mediated lysis, especially during sleep (when urine is concentrated and acidic, triggering complement activation). The result is hemolysis, thrombosis, and bone marrow failure. PNH is diagnosed by flow cytometry demonstrating absence of GPI-anchored proteins (CD55, CD59, CD16, CD24) on blood cells. The hallmark clinical triad includes hemolytic anemia, thrombosis (venous > arterial), and cytopenias. Indian patients often present with dark urine (hemoglobinuria), thrombotic complications (Budd-Chiari syndrome, mesenteric vein thrombosis), and aplastic anemia overlap. Treatment includes complement inhibitors (eculizumab, pegcetacoplan) and anticoagulation.

Why the other options are wrong

A. Chediak-Higashi syndrome — Chediak-Higashi syndrome is a lysosomal storage disorder caused by mutations in the LYST gene, affecting granule formation in neutrophils, leading to recurrent infections and oculocutaneous albinism. It has no relationship to CD59 or complement regulation. This is a distractor that tests knowledge of rare immunodeficiency syndromes but is unrelated to the GPI-anchor defect in PNH. B. Primary myelofibrosis — Primary myelofibrosis is a myeloproliferative neoplasm characterized by JAK2, CALR, or MPL mutations, leading to bone marrow fibrosis and extramedullary hematopoiesis. Although PNH can overlap with aplastic anemia or myelodysplasia, myelofibrosis itself is not a GPI-anchor disorder and has no direct link to CD59 deficiency. This option confuses hematologic complications. D. Essential thrombocythemia — Essential thrombocythemia is a myeloproliferative neoplasm (JAK2, CALR, or MPL mutations) presenting with sustained thrombocytosis and thrombotic/hemorrhagic complications. While PNH patients may develop thrombosis, ET is not a complement-mediated or GPI-anchor disorder. This option exploits the overlap of thrombotic manifestations between PNH and ET.

High-Yield Facts

Mnemonics

PNH = GPI-Anchor Loss GPI-anchor defect → Protein (CD59, CD55) loss → Hemolysis, thrombosis, cytopenias. PIGA mutation → no GPI → no CD59 → no MAC inhibition → complement-mediated lysis. CD59 = Complement Stop Sign CD59 blocks the final step of complement (MAC assembly at C5b-9). Without it, cells are lysed. In PNH, this 'stop sign' is missing → unchecked hemolysis.

NBE Trap

NBE pairs PNH with thrombotic complications to lure students into selecting myeloproliferative neoplasms (ET, primary myelofibrosis), which also cause thrombosis. The discriminator is that PNH is a complement-mediated disorder (CD59 deficiency), not a clonal myeloid disorder.

Clinical Pearl

In Indian practice, PNH often presents as "hemolytic anemia with thrombosis"—a combination that mimics autoimmune hemolytic anemia but with thrombotic complications (Budd-Chiari, portal vein thrombosis) that are rare in AIHA. Flow cytometry for GPI-anchored proteins is the gold standard diagnostic test and should be ordered whenever hemolysis is accompanied by unexplained thrombosis or cytopenias.

_Reference: Robbins Ch. 13 (Blood and Bone Marrow); Harrison Ch. 109 (Hemolytic Anemias)_